Evidence map›Paper›PMID 34225463›Full record

ArticleJournal of evidence-based integrative medicine

20-Week Study of Clinical Outcomes of Over-the-Counter COVID-19 Prophylaxis and Treatment.

Leon Margolin, Jeremy Luchins, Daniel Margolin, Michelle Margolin, Sanford Lefkowitz

Abstract readControlled Clinical Trial
In one paragraph

Article in Journal of evidence-based integrative medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. COVID-19: an 'extraterrestrial' disease?International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Article
  12. Potential of Quinine Sulfate for COVID-19 Treatment and Its Safety Profile: Review.Clinical pharmacology : advances and applications · 2021
    Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Leon MargolinComprehensive Pain Management Institute, LLC, Columbus, OH, USA.ORCID https://orcid.org/0000-0002-0642-300X
Jeremy LuchinsComprehensive Pain Management Institute, LLC, Columbus, OH, USA.ORCID https://orcid.org/0000-0003-2806-6872
Daniel MargolinComprehensive Pain Management Institute, LLC, Columbus, OH, USA.
Michelle MargolinComprehensive Pain Management Institute, LLC, Columbus, OH, USA.
Sanford LefkowitzComprehensive Pain Management Institute, LLC, Columbus, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

OBJECTIVES AND SETTING.: As the lethal COVID-19 pandemic enters its second year, the need for effective modalities of alleviation remains urgent. This includes modalities that can readily be used by the public to reduce disease spread and severity. Such preventive measures and early-stage treatments may temper the immediacy of demand for advanced anti-COVID measures (drugs, antibodies, vaccines) and help relieve strain also on other health system resources. DESIGN AND PARTICIPANTS.: We present results of a clinical study with a multi-component OTC "core formulation" regimen used in a multiply exposed adult population. Analysis of clinical outcome data from our sample of over 100 subjects - comprised of roughly equal sized regimen-compliant (test) and non-compliant (control) groups meeting equivalent inclusion criteria - demonstrates a strong statistical significance in favor of use of the core formulations. RESULTS.: While both groups were moderate in size, the difference between them in outcomes over the 20-week study period was large and stark: Just under 4% of the compliant test group presented flu-like symptoms, but none of the test group was COVID-positive; whereas 20% of the non-compliant control group presented flu-like symptoms, three-quarters of whom (15% overall of the control group) were COVID-positive. CONCLUSIONS.: Offering a low cost, readily implemented anti-viral approach, the study regimen may serve, at the least, as a stopgap modality and, perhaps, as a useful tool in combatting the pandemic.

Indexed as

Communicable Disease ControlCOVID-19 Drug TreatmentDietary SupplementsPandemicsAdultAntiviral AgentsCinchonaCOVID-19FemaleHumansIonophoresLysineMaleMiddle AgedNonprescription DrugsQuercetinAntiviral AgentsIonophoresLysineNonprescription DrugsQuercetinVitaminsZincCOVID-19early-stage treatmentimmunity enhancementionophoresOTCprophylaxisregimen complianceSARS-CoV-2zinc

Identifiers

PMID34225463
PMCPMC8264737

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.